Holen Sie sich die Stockscreener-App
12.00
0.58%
-0.07
Handel nachbörslich:
12.55
0.55
+4.58%
Schlusskurs vom Vortag:
$12.07
Offen:
$11.65
24-Stunden-Volumen:
629.82K
Relative Volume:
0.48
Marktkapitalisierung:
$741.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-5.3571
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
-3.46%
1M Leistung:
+55.04%
6M Leistung:
+141.45%
1J Leistung:
+35.75%
1-Tages-Spanne:
$11.50
$12.30
1-Wochen-Bereich:
$11.50
$13.22
52-Wochen-Spanne:
$3.5001
$13.22
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
12.00 | 745.44M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.2025 Earnings Surprises & Entry Point Strategy Guides - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsChart Signals & Capital Protection Trade Alerts - newser.com
What to do if you’re stuck in Monte Rosa Therapeutics Inc.Weekly Earnings Recap & Accurate Intraday Trading Signals - newser.com
Published on: 2025-11-04 01:29:55 - newser.com
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Monte Rosa Therapeutics (NASDAQ: GLUE) sets investor chats; 30-day webcasts available - Stock Titan
Is it time to cut losses on Monte Rosa Therapeutics Inc.Earnings Recap Report & Long-Term Safe Investment Plans - newser.com
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Decliners & Accurate Technical Buy Alerts - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionWeekly Stock Report & High Return Trade Guides - newser.com
Chart based exit strategy for Monte Rosa Therapeutics Inc.2025 Top Gainers & Community Verified Trade Signals - newser.com
Forecasting Monte Rosa Therapeutics Inc. price range with options dataMarket Movers & Safe Entry Trade Reports - newser.com
Cwm LLC Raises Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (GLUE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Monte Rosa Therapeutics, Inc. (GLUE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Monte Rosa Therapeutics (NASDAQ:GLUE) Given Sell (D+) Rating at Weiss Ratings - MarketBeat
Monte Rosa Therapeutics Hits New 52-Week High of $13.10 - Markets Mojo
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Visual trend scoring systems applied to Monte Rosa Therapeutics Inc.Weekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study - MSN
Monte Rosa Therapeutics Hits New 52-Week High of $12.97 - Markets Mojo
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study - MSN
What analysts say about Monte Rosa Therapeutics Inc stockDividend Reinvestment Plans & Small Investment Growth Tips - earlytimes.in
How Regulatory Changes Could Impact ICDS Limiteds BusinessRelative Strength Index (RSI) & Learn to Trade Without Fear of Loss - earlytimes.in
Working capital per share of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):